What I am finding says it was a 50/50 Profit split.
I have put a link from the announcement and then asked ChatGPT that very specific question. Here is the response;
"The agreement between Janssen and Pharmacyclics was indeed a **50/50 profit split**, where both companies equally shared profits and losses related to the development and commercialization of PCI-32765 (Ibrutinib). This profit-sharing approach differed from a traditional royalty-based structure."
https://www.jnj.com/media-center/press-releases/janssen-biotech-inc-announces-collaborative-development-and-worldwide-license-agreement-for-investigational-anti-cancer-drug-pci-32765
CPACS: Research, Results, Market Comparisons, and Valuations, page-252
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.42 |
Change
-0.045(3.07%) |
Mkt cap ! $242.0M | |||
| Open | High | Low | Value | Volume |
| $1.49 | $1.49 | $1.41 | $238.0K | 164.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300 | $1.43 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 2011 | 1 |
View Market Depth
| Last trade - 15.55pm 14/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |